---

---

sector : Professional, scientific, and technical services    tags : Cancer   

save search

---

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -3.83% | O: -3.83% H: 0.0% C: 0.0%
breast cancer preclinical for

---

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
CMPX | $1.48 -0.67% -0.68% 230K |

Professional, Scientific, and T...

| -13.53% | O: 2.06% H: 0.0% C: 0.0%
association tumors cancer research for meeting therapeutics negative

---

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -2.13% | O: 1.77% H: 0.0% C: 0.0%
breast cancer system

---

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K |

Professional, Scientific, and T...

| -18.25% | O: -1.59% H: 8.87% C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform

---

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
MDXH | $2.37 1.72% 1.69% 48K |

Professional, Scientific, and T...

| Email alert Add to watchlist
test genetic cancer offering

---

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
Published: 2024-03-11 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K |

Professional, Scientific, and T...

| -31.33% | O: 2.86% H: 0.0% C: -11.14%
report genomics cancer treatment technology therapeutics

---

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -11.54% | O: -0.64% H: 4.52% C: -6.45%
breast cancer

---

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -18.82% | O: 0.0% H: 3.79% C: -8.24%
conference breast cancer system

---

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 23:00) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K |

Professional, Scientific, and T...

| -27.29% | O: 2.59% H: 16.28% C: 14.68%
six association cancer research meeting therapeutics

---

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
ELEV | $3.79 -5.49% -5.8% 990K |

Professional, Scientific, and T...

| -18.63% | O: 1.71% H: 2.95% C: -1.68%
association cancer research preclinical meeting program

---

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -33.33% | O: 1.69% H: 0.95% C: -6.53%
breast cancer

---

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Published: 2024-02-06 (Crawled : 13:30) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -29.77% | O: 9.41% H: 1.16% C: -3.72%
candidate cancer

---

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 -6.31% 66K |

Professional, Scientific, and T...

| -71.62% | O: 2.03% H: 0.66% C: -11.26%
sbp-101 association presentation cancer research

---

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K |

Professional, Scientific, and T...

| -36.83% | O: 14.42% H: 1.21% C: -10.29%
cancer collaboration therapeutics

---

Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
AKYA | $3.81 -1.04% -1.05% 170K |

Professional, Scientific, and T...

| -23.54% | O: 1.41% H: 2.38% C: -3.17%
cancer treatment technology

---

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Published: 2024-01-04 (Crawled : 14:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -44.8% | O: 2.8% H: 8.75% C: 3.7%
breast cancer

---

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
Published: 2023-12-28 (Crawled : 14:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -47.43% | O: 1.71% H: 9.55% C: 2.43%
breast cancer system advanced response

---

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
RNAZ | $0.49 -2.39% -2.45% 110K |

Professional, Scientific, and T...

| -93.6% | O: 11.94% H: 0.0% C: -19.05%
mc138 pre-clinical animal positive cancer pancreatic therapeutics results

---

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
Published: 2023-12-12 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K |

Professional, Scientific, and T...

| -93.6% | O: 11.94% H: 0.0% C: -19.05%
mc138 ttx-mc138 pre-clinical positive cancer pancreatic therapeutics results

---

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
Published: 2023-12-06 (Crawled : 14:30) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -47.53% | O: 3.23% H: 0.18% C: -6.81%
breast cancer sabcs topline advanced

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---